FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 217 filers reported holding FATE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.68 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $42,527,968 | -83.7% | 4,214,863 | -63.8% | 0.37% | -79.7% |
Q3 2022 | $261,207,000 | -1.4% | 11,655,833 | +1.6% | 1.82% | +16.2% |
Q2 2022 | $265,041,000 | -37.8% | 11,473,655 | +4.4% | 1.57% | -11.9% |
Q1 2022 | $426,012,000 | -29.4% | 10,988,182 | +6.6% | 1.78% | -2.5% |
Q4 2021 | $603,365,000 | -6.6% | 10,312,167 | -5.4% | 1.82% | +17.5% |
Q3 2021 | $646,177,000 | -0.5% | 10,902,258 | +45.7% | 1.55% | +28.4% |
Q2 2021 | $649,458,000 | +20.2% | 7,483,102 | +14.2% | 1.21% | +12.7% |
Q1 2021 | $540,422,000 | +104.8% | 6,554,546 | +125.9% | 1.07% | +52.8% |
Q4 2020 | $263,852,000 | +358.4% | 2,901,700 | +101.5% | 0.70% | +105.9% |
Q3 2020 | $57,556,000 | +64.5% | 1,439,970 | +41.2% | 0.34% | -9.3% |
Q2 2020 | $34,990,000 | +183.8% | 1,019,830 | +83.7% | 0.38% | +22.5% |
Q1 2020 | $12,328,000 | +46.1% | 555,082 | +28.8% | 0.31% | +44.1% |
Q4 2019 | $8,437,000 | +60.2% | 431,128 | +27.2% | 0.21% | +85.2% |
Q3 2019 | $5,265,000 | +16.8% | 339,039 | +52.7% | 0.12% | +0.9% |
Q2 2019 | $4,508,000 | – | 222,064 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |